Navigation Links
Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association
Date:6/14/2008

MONTREAL, June 14 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") today presented results on its orally-active PBI-1402 compound in clinical trial in patients with chemotherapy-induced anemia ("CIA") at the 13th Congress of the European Hematology Association held in Copenhagen, Denmark this week.

Dr. Lyne Gagnon, ProMetic's Director R&D, Biology, presented data on PBI-1402 in a poster entitled "PBI-1402 increases hemoglobin level and red blood cell count in chemotherapy-induced anemia". Results demonstrated that a once daily oral treatment of PBI-1402 induces a significant increase in hemoglobin ("Hb") level, red blood cell ("RBC") count and hematocrit ("Ht") in CIA patients. Furthermore, results suggest that PBI-1402 can reduce the need for RBC transfusion, since only 6% of patients in the clinical trial required transfusion.

"Subsequent positive data compiled from the 28 patients having completed the PBI-1402 CIA clinical trial include the fact that 26 of these patients did not require RBC transfusions while maintaining their full chemotherapy regimen. This data further supports that PBI-1402's current performance is in line with the Food and Drug Administration's ("FDA") recommendation of reducing patient need for RBC transfusions," states Mr. Pierre Laurin, ProMetic's President and Chief Executive Officer. "Additionally, PBI-1402 offers the added advantage of oral dosing which allows for a convenient management of anemia without interference with other treatments received by the CIA patients."

In the March 13, 2008 briefing document, the FDA's Oncologic Drugs Advisory Committee emphasized that the primary objective of treating CIA patients with erythropoiesis-stimulating agents ("ESAs") as being the ability to reduce the need for RBC transfusions. Approximately 50% of anemic patients receiving chemotherapy require RBC transfusions, and 20%-25% of patients treated with ESAs still require RBC transfusions.
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
2. QLT announces positive Health Canada decision on Aczone(R)
3. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
4. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
5. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
6. First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
9. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
10. Liver Diseases: A Huge European Health Burden, But Some Trends are Positive
11. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., , CRANBURY, N.J., Dec. 1 /PRNewswire-Firs...PTN ) today announced that the U.S. Patent and Tra..., titled "Cyclic Natriuretic Peptide Constructs." ... cyclic compounds that bind to natriuretic peptide...ead heart failure drug candidate. ,, "Our natri...
(Date:12/1/2009)..., , HUNTINGTON BEACH, California a...a world leader in molecular cancer diagnostics, an... B Medicare administrator, has established,coding ...aPrint is Agendia,s,FDA-cleared breast cancer recu...ince 2008. , Patients across the United S...
(Date:12/1/2009)..., , HARBIN, China, Dec. 1 /PRNe...nc. ("China Sky One Medical" or "the Company") (Na...utical company developing and producing,over-the-c...RC"), today,announced that the Company has engaged...ervice Company ("MDK") to serve as its exclusive s...
(Date:12/1/2009)..., , NEW YORK and MONTREAL, Dec. 1 /PRNewswir...partner -ICBS Ltd. (OTCPK: ICBT), announced today ...mp; Manufacturing Inc., of Canada for the manufact... distribution in the U.S. ,, "We have seen the ... in fresh vegetables and packaged salads in the pa...
Breaking Biology Technology:Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 3Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint(R) 2China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 2China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 3
..., Wis. -- Network Health Plan , Affinity Health S...sin, and HealthTrio announced today the availabi...mbers, employers and brokers through HealthTrio co... , ,NHP will launch the product suite in two phase...rting this summer, NHPs providers will be able to ...
...rporate executives seem taken aback by the anger e... they should not be surprised at all. US workers h...eengineered for over two decades. The past four ye...r jobs during this period have experienced great d...singly, they are bitter and scared. Many survived ...
... - EraGen Biosciences , a Madison-based life scie...to a collaboration agreement with Emory Universit...ful in the early detection of the HIV variants. Th... ,The goal of the collaboration will be to develop...or early response to therapeutic resistance. As pa...
Other Biology Technology:The "Big Squeeze" - Look for a job or be an entrepreneur? 2The "Big Squeeze" - Look for a job or be an entrepreneur? 3
(Date:12/1/2009)...National Primate Research Center, Emory University... prairie voles, an important step toward unlocking...application of this technology will enable scienti...t will help identify the brain mechanisms of socia... advancement may also have important implications ...
(Date:12/1/2009)... University cancer researchers have developed a t...ells and blocks the growth of new tumor blood vess...d to kill cancer cells oncolytic viruses might b...f they also carry a gene for a protein that inhibi...culostatin, is normally produced in the brain. In ...
(Date:12/1/2009)... 1 iQor, a global provider of busi...ded in the 2009 InfoWorld 100 Awards Top 100 IT ...em, TeQ21. This was the first submission for iQor.... prestigious list of companies," said Vikas Kapoor...transforming the way we do business, allowing us t...
Breaking Biology News(10 mins):Yerkes researchers create first transgenic prairie voles 2Tumor-attacking virus strikes with 'one-two punch' 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2ComCam Selected by ePortation on New Maritime Domain Awareness Project 9477 1ComCam Selected by ePortation on New Maritime Domain Awareness Project 9477 2UBC researchers find first ever wanderlust gene in tiny bony fish 9474 1100+ Nurses to Rally in SF Wed to Demand Stronger Swine Flu Safety Protections 3A California Hospitals Remain Unprepared Despite First Nurse Death 53680 1100+ Nurses to Rally in SF Wed to Demand Stronger Swine Flu Safety Protections 3A California Hospitals Remain Unprepared Despite First Nurse Death 53680 2100+ Nurses to Rally in SF Wed to Demand Stronger Swine Flu Safety Protections 3A California Hospitals Remain Unprepared Despite First Nurse Death 53680 3
...rve University School of Medicine have discovered ...esses our sense of smell. This new cell type, the ...unstudied brain cells described by the Spanish neu...te 1800s. Blanes cells have unusual properties wh... and also opens a new approach to understanding th...
...t Georgia State University and the Atlanta-based C...at anatomical and functional differences in the br...of pain and in the effects of certain drugs on pai... of the Journal of Comparative Neurology, is the f...f the brain responsible for the transmission of pa...
... 1 & 2 , Chemists at Harvard University h...-time, molecule-by-molecule "movie" of protein pro... fluorescently tagged molecules in single cells --... of individual new protein molecules inside -- gre...netic activity. , Using the new assay, described t...
Other Biology News:Neuroscientists discover new cell type that may help brain maintain memories of smells 2Neuroscientists discover new cell type that may help brain maintain memories of smells 3Brain differences could explain why males and females experience pain relief differently 2Molecule by molecule, new assay shows real-time gene activity 2Molecule by molecule, new assay shows real-time gene activity 3
Biolase Red DNA Polymerase from Bioline
Rabbit Anti-Human XM_941015 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Cag-A-directed IgG EIA Kit from Alpco Diagnostics
...itor that noncovalently binds and inactivates neut... is seen with RNase 1, T1, T2, H, U1, U2 or CL3. A...lease inhibitor in that it has a more robust inter...e in the absence of DTT or other reducing agents. ...
Biology Products: